IP Library › Granted Patent US 12661345
Granted Patent B2
US 12661345 · App. 19/386,124 · Granted Jun 23, 2026

Compositions for the treatment of hypertension

Inventors: Anthony Rodgers (Newtown, AU); Stephen MacMahon (Newtown, AU)
Assignee: THE GEORGE INSTITUTE FOR GLOBAL HEALTH
A61K31/4422A61K31/277A61K31/382A61K31/40A61K31/4035A61K31/404A61K31/41A61K31/4178A61K31/4184A61K31/4418A61K31/495A61K31/517A61K31/549A61K31/554A61P9/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661345
App. No.
19/386,124
Granted
Jun 23, 2026
Kind
B2
Abstract

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Claims (18)

1 . A pharmaceutical composition for the treatment of hypertension, the pharmaceutical composition comprising:

(a) telmisartan;

(b) indapamide; and

(c) amlodipine besylate, wherein a dose of the telmisartan is about 30 milligrams (mg) to about 50 mg, a dose of the indapamide is about 1.875 mg to about 3.125 mg, and a dose of the amlodipine besylate is about EQ 3.75 mg base to about EQ 6.25 mg base;

wherein the pharmaceutical composition is free of a beta blocker; and

wherein the pharmaceutical composition comprises one or more cholesterol-lowering agents selected from ezetimibe, rosuvastatin, or a combination thereof.

2 . The pharmaceutical composition of claim 1 , wherein the dose of the telmisartan is about 40 mg.

3 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg.

4 . The pharmaceutical composition of claim 1 , wherein the dose of the amlodipine besylate is about EQ 5 mg base.

5 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg and the dose of amlodipine besylate is about EQ 5 mg base.

6 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg and the dose of the telmisartan is about 40 mg.

7 . The pharmaceutical composition of claim 1 , wherein the dose of the amlodipine besylate is about EQ 5 mg base and the dose of the telmisartan is about 40 mg.

8 . The pharmaceutical composition of claim 1 , wherein the dose of the indapamide is about 2.5 mg, the dose of the amlodipine besylate is about EQ 5 mg base, and the dose of the telmisartan is about 40 mg.

9 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is provided in the form of a pill or a tablet.

10 . The pharmaceutical composition of claim 1 , wherein the at least one cholesterol-lowering active agent is a combination of ezetimibe and rosuvastatin.

11 . The pharmaceutical composition of claim 9 , wherein a dose of the ezetimibe is about 10 mg, and wherein a dose of the rosuvastatin is about 10 mg.

12 . A method of treating at least one of hypertension and dyslipidemia in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 1 .

13 . A method of treating a combination of hypertension and dyslipidemia in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 1 .